StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD – Free Report) in a report published on Saturday. The brokerage issued a sell rating on the medical equipment provider’s stock.
Separately, HC Wainwright cut their target price on shares of Aethlon Medical from $10.00 to $7.00 and set a buy rating for the company in a research report on Monday, June 24th.
Read Our Latest Stock Analysis on Aethlon Medical
Aethlon Medical Price Performance
Aethlon Medical (NASDAQ:AEMD – Get Free Report) last posted its earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.10. During the same quarter in the prior year, the firm posted ($1.30) EPS. As a group, analysts anticipate that Aethlon Medical will post -1.1 earnings per share for the current year.
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Read More
- Five stocks we like better than Aethlon Medical
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- MarketBeat Week in Review – 9/16 – 9/20
- The Most Important Warren Buffett Stock for Investors: His Own
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.